Using the same lysates from which the immunoprecipitations were performed, we verified that treatment of these breast cancer cells with Dasatinib or PP2 effectively inhibited Src and FAK activation, while vehicle treatment (dimethylsulphoxide) had no effect (Supplementary Fig. 10). This evidence concerns the gene PTK2 and breast carcinoma.